An observational study in Thyroid Cancer, sponsored by Shandong Provincial Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-10-02.
Sponsored by Shandong Provincial Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 160 studies in Thyroid Neoplasms with a site in China — 65 open to participants now, 72 under way, 6 of them phase 3. Thyroid Neoplasms · China.
Among the 160 studies in Thyroid Neoplasms with a site in China, this one is the 9th largest by planned enrollment of the 52 observational ones that give a count, is the only one that started in 2012, is one of 52 observational ones, reaches primary completion later than 28 of the 71 other live ones, and was the 111th registered.
785 studies on the registry are indexed under Thyroid Neoplasms; 203 are open to participants now.
Browse Thyroid Neoplasms studies →65 of the 160 studies in Thyroid Neoplasms with a site in China are open now. Recruiting first, the newest first:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–80
Shanghai 6th People's Hospital · Sites in China
Ages 18–60
Fudan University · Sites in China
Ages 18+
The First Affiliated Hospital of Xiamen University · Sites in China
Ages 18–90
FindCure Biosciences (ZhongShan) Co., Ltd. · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 151 Thyroid Neoplasms studies recruiting now, 95 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 36 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
160 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 41 · Phase 3 14 · Phase 4 5
First in 2006; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,600 is above the median of 178 across 241 observational studies indexed under Thyroid Neoplasms.
Median enrollment 106 across the 108 interventional studies, 300 across the 52 observational. Of the 47 that completed or were terminated, 6 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 160 have an industry lead sponsor. The 10 most frequent:
Shandong Provincial Hospital is the lead sponsor of 64 studies on the registry; 26 are open to participants now.
Shandong Provincial Hospital has 4 studies filed under Thyroid Neoplasms — fewer than ten, so there is no comparison to draw.
17 of the studies in Thyroid Neoplasms with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06860971Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma | 2027-01 |
| NCT07459283FindCure Biosciences (ZhongShan) Co., Ltd.The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors | 2026-12 |
| NCT06623500Shandong Provincial HospitalIodine Nutrition Status and Clinical Characteristics of Thyroid Cancer | 2026-12-01 |
| NCT07359586Zhejiang UniversityLaryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia | 2026-12-25 |
| NCT06970353Fudan UniversityPhase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer | 2026-12-30 |
Add all 17 to your calendar (.ics) → With an account.
Among the 160 studies in Thyroid Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The effect of iodine nutritional status on thyroid cancer has been controversial for many years. We designed a prospective cohort study that recruiting patients in different iodine areas who underwent thyroid cancer surgery in branch hospitals from 2012 to 2019,and follow up their clinical outcomes. We aimed to analyse the relationship between regional iodine nutrition level and pathological types, clinical features, and prognosis of thyroid cancer.
Three sub centers were selected in high iodine (Jining/Liaocheng/Heze) and moderate iodine (Jinan/Shenyang/Haerbin) areas respectively. Patients lived in the above-mentioned regions for at least 5 years and diagnosed as thyroid cancer and underwent thyroid surgery in branch hospitals from 2012 to 2019 were recruited.
Three sub centers were selected in high iodine (Jining/Liaocheng/Heze) and moderate iodine (Jinan/Shenyang/Haerbin) areas respectively. Patients lived in the above-mentioned regions at least for 5 years who was diagnosed as thyroid cancer and underwent thyroid surgery in branch hospitals from 2012 to 2019 were recruited.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Residents with thyroid cancer who have lived in high iodine areas for a long time (5 years or more). According to the report of Shandong Institute of Endemic Disease Prevention and Control, three sub centers were selected in Excessive iodine group (Jining/Liaocheng/Heze).
Dietary Supplement: Iodine excess
Residents with thyroid cancer who have lived in suitable iodine areas for a long time (5 years or more). According to the report of Shandong Institute of Endemic Disease Prevention and Control, three sub centers were selected in suitable iodine (Jinan/Shenyang/Haerbin) areas.
Dietary Supplement: Iodine suitable
Iodine excess areas: water iodine ≥100μg/L; or urinary iodine concentration (median urinary iodine levels in children aged 8-10 years old)≥300μg/L
Iodine suitable areas:water iodine ≥40μg/L and ≤100μg/L; or urinary iodine concentration(median urinary iodine levels in children aged 8-10 years old) 100-199μg/L.
Number of participants with recurrence
Recurrence: diagnosed as the same type of thyroid cancer again by pathology
Time frame: from enrollment to the final follow-up at 5 years
Number of participants with distant metastasis
Distant metastasis: Pathological confirmed thyroid cancer occurring outside the thyroid gland
Time frame: from enrollment to the final follow-up at 5 years
All-cause mortality
The ratio of the total number of deaths caused by various reasons during the research period to the number of participants
Time frame: from enrollment to the final follow-up at 5 years
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2012 (actual). Primary completion is estimated for Dec 2026, 179 months after the start.
Of 103 non-industry observational studies under Thyroid Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 311. This study's planned 179 months is above that.
Counting every sponsor, half of 112 studies reached it within 63 months; a quarter within 26 and three quarters within 311.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shandong Provincial Hospital